Avalon GloboCare (NASDAQ:ALBT) Trading Down 1.1% – What’s Next?

Avalon GloboCare Corp. (NASDAQ:ALBT)’s stock price traded down 1.1% on Friday . The company traded as low as $0.2610 and last traded at $0.2790. Approximately 9,336,703 shares were traded during trading, an increase of 194% from the average daily volume of 3,170,642 shares. The stock had previously closed at $0.2820.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare has an average rating of “Sell”.

Avalon GloboCare Stock Performance

The business has a fifty day moving average of $0.30 and a two-hundred day moving average of $0.48. The firm has a market capitalization of $4.05 million, a price-to-earnings ratio of -0.08 and a beta of -0.03.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.